Almost 60% of our patients had type 2 diabetes, and over 70% of patients have CKD; therefore, present study could observe the effect of a novel selective URAT1 inhibitor, dotinurad on metabolic and renal parameters in CKD and DKD patients. This evidence concerns the gene SLC22A12 and diabetic kidney disease.